Tuesday, Apr 30, 1996
South San Francisco, Calif. -- April 30, 1996 --Genentech, Inc. (NYSE: GNE) today announced the appointment of Robert Arathoon, Ph.D., as vice president of Process Sciences. In this post, he will oversee an organization of about 240 people, including 65 Ph.D.'s, that designs and develops all the processes Genentech uses to produce proteins as pharmaceuticals for research, clinical trials and the market.
"Arathoon has led the development of our processes for manufacturing many of Genentech's currently marketed products and those in late stages of clinical development," said Executive Vice President William D. Young. "His demonstrated knowledge and leadership ability make him the ideal person to lead Genentech's process sciences group as it continues to develop efficient, economical and innovative processes for manufacturing our pharmaceutical products to be able to deliver them reliably to patients."
Arathoon has more than 20 years experience in the pharmaceutical and biotechnology industries, including 13 years at Genentech since he joined the company in 1983 as a scientist in the Applied Cell Culture department. After a series of promotions, he was named director of Cell Culture R&D in 1988 and senior director of Cell Culture and Fermentation R&D in 1994. Earlier this year, he was promoted to senior director of Process Sciences. Prior to joining Genentech, Arathoon spent 8 years at the Wellcome Foundation in various Process Development roles.
Arathoon earned a bachelor of science degree in biochemistry and physiology, a master of science degree in industrial microbiology, and a Ph.D. in cell culture and virology, all from the University of London.
Genentech's Process Sciences group, generally recognized as the industry leader in process development of protein pharmaceuticals, includes the Cell Culture and Fermentation R&D, Recovery Sciences, Pharmaceutical R&D, Analytical Chemistry, and Cell Banking and Characterization departments.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Ten of the currently marketed biotechnology products stem from Genentech science, five of which Genentech markets directly in the United States. Genentech is headquartered in South San Francisco, California, and is traded on the New York and Pacific Stock Exchanges under the symbol GNE. Genentech's world wide web address is http://www.gene.com.
# # #